Physician profile
Donald E Lindblad
NPI 1821090887
$623.74
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $267 · 2020: $93.70 · 2021: $153 · 2022: $110.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Therapeuticsmd, INC. | $229.42 | 2019-2021 | |
| Amag Pharmaceuticals, INC. | $96.45 | 2019-2020 | |
| Hologic Sales and Service, LLC | $69.95 | 2020-2022 | |
| Abbvie INC. | $60.40 | 2019-2022 | |
| Evofem Biosciences, INC. | $37.89 | 2021 | |
| Channel Medsystems, INC. | $28.00 | 2022 | |
| Ascend Therapeutics US, LLC | $23.43 | 2022 | |
| Agile Therapeutics, INC. | $23.41 | 2021 | |
| Baxter Healthcare | $23.40 | 2019 | |
| Merck Sharp & Dohme LLC | $17.62 | 2020 | |
| Myovant Sciences INC. | $13.77 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donald Lindblad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.